Two Clinical Studies Support Efficacy of Pure Encapsulations® Resveratrol
Polyphenol found in grapes and red wine moderates cytokine levels with once-daily dosing

December 05, 2013 – Sudbury, MA – Pure Encapsulations®, a leading manufacturer of hypo-allergenic nutritional supplements, announces the findings of two studies utilizing Pure Encapsulations® Resveratrol. Conducted by academic researchers, these independent clinical investigations diverged from prior research studies on resveratrol by evaluating the product at a once-daily dose.

Since the 1990s, scientists have known that resveratrol moderates nuclear factor kappa B (NFκB), a master switch of cytokine gene expression in cell culture.  Dozens of studies have since attributed this mechanism to its cardioprotective and neuroprotective effects.  However, these clinical studies used high doses, typically 100-500 mg per day, leaving questions about the ability of resveratrol to provide support at a lower dose.

“While the clinical value of resveratrol is widely recognized, health care professionals must navigate an overwhelming array of formulations and doses,” states Kelly Heim, Ph.D., a pharmacologist at Pure Encapsulations®. “The new studies on Pure Encapsulations’ Resveratrol allow the practitioner to select and apply our product with confidence.  This research is among many examples of Pure Encapsulations’ alignment with evidence-based medicine.”

  • In the first randomized, placebo-controlled study, researchers from the State University of New York at Buffalo examined the effect of one capsule, providing 40 mg resveratrol daily, on oxidative and immunologic markers in healthy human subjects.  The results, published in The Journal of Clinical Endocrinology and Metabolism (2010) indicated statistically significant and favorable changes in oxidative stress and levels of cytokines, such as TNF-alpha and interleukin-6, after 3 weeks.
  • The second randomized, placebo-controlled study, conducted at Tehran University of Medical Sciences in Tehran, Iran, evaluated the effects of the same dose on cytokine levels in professional basketball players over an intense 6-week training period.  The results, published in The International Journal of Preventive Medicine (2013) indicated statistically significant moderation of TNF-alpha and interleukin-6 in the group receiving resveratrol relative to placebo.

“Concerns about the bioavailability of resveratrol have driven many researchers to use high doses of isolated forms for the clinical trials, “states Dr. Heim.  “However, these two studies show that a low dose from a natural plant source can deliver measurable results in a matter of weeks.”

For more information on PureHeart™ Probiotic, or to request a copy of The PureHeart™ Protocol: Screening + Supplements = Success™ brochure, please contact Bryanna Charbonneau at or visit

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

About Pure Encapsulations®
A business unit of Atrium Innovations Inc. (TSX: ATB), Pure Encapsulations is committed to producing a complete line of research-based nutritional supplements. Available through health professionals, finished products are pure and hypo-allergenic to optimize the long-term health of the most sensitive patients. Pure Encapsulations is an industry leader in quality, with an extensive raw material and finished product testing program that includes analysis for identity, potency, environmental contaminants, oxidation and more by certified third party laboratories. Pure Encapsulations is NSF-GMP registered in the U.S., GMP certified in Canada and exceeds the standards of the United States Pharmacopeia (USP) for supplement manufacturing. For additional information, please visit For more information about Micropharma, visit

About Atrium Innovations
Atrium Innovations Inc. (TSX: ATB) is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based natural health products which are distributed in more than 35 countries.  The Company owns healthcare practitioner and specialized retail product brands that are at the forefront of science, innovation and education.  Atrium has over 1,100 employees and operates seven manufacturing facilities complying with current Good Manufacturing Practices. Additional information is available at

Media Contact:

Bryanna Charbonneau

Pure Encapsulations

p: 800-753-2277